PR Newswire Clinical TrialsOriginal article
Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133
Phase 1RBD3133Positive
AI Analysis
Summary
Ribo announced successful submission of a Phase 1 Clinical Trial Application to the European Union for RBD3133, an INHBE-targeting siRNA therapeutic.
Clinical Trial Data
Phase
Phase 1
Outcome Details
Clinical Trial Application submitted to EU
Importance:5/10
Sentiment:
0.50
siRNAEuropeclinical_trialregulatory_submission
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 8, 2026 2:57 AM